Inovio Pharmaceuticals (INO) Short Interest Ratio & Short Volume $1.39 +0.02 (+1.46%) Closing price 04:00 PM EasternExtended Trading$1.41 +0.02 (+1.44%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Inovio Pharmaceuticals Short Interest DataInovio Pharmaceuticals (INO) has a short interest of 5.50 million shares, representing 10.88% of the float (the number of shares available for trading by the public). This marks a -14.86% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.3, indicating that it would take 4.3 days of the average trading volume of 842,122 shares to cover all short positions.Current Short Interest5,500,000 sharesPrevious Short Interest6,460,000 sharesChange Vs. Previous Month-14.86%Dollar Volume Sold Short$11.22 millionShort Interest Ratio4.3 Days to CoverLast Record DateJune 30, 2025Outstanding Shares36,670,000 sharesFloat Size50,560,000 sharesShort Percent of Float10.88%Today's Trading Volume1,867,273 sharesAverage Trading Volume842,122 sharesToday's Volume Vs. Average222% Short Selling Inovio Pharmaceuticals? Sign up to receive the latest short interest report for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartINO Short Interest Over TimeINO Days to Cover Over TimeINO Percentage of Float Shorted Over Time Inovio Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/20255,500,000 shares $11.22 million -14.9%10.9%4.3 $2.04 6/15/20256,460,000 shares $12.92 million -1.7%17.8%10.1 $2.00 5/31/20256,570,000 shares $13.34 million -6.3%18.1%10 $2.03 5/15/20257,010,000 shares $13.67 million +8.5%19.3%11.2 $1.95 4/30/20256,460,000 shares $12.53 million -3.3%17.7%9.7 $1.94 4/15/20256,680,000 shares $11.76 million +4.4%18.3%9.4 $1.76 3/31/20256,400,000 shares $10.43 million +19.6%17.6%7.5 $1.63 3/15/20255,350,000 shares $10.86 million -3.1%14.7%6 $2.03 2/28/20255,520,000 shares $10.93 million +2.6%15.4%5.2 $1.98 2/15/20255,380,000 shares $11.57 million +7.4%15.0%5.2 $2.15 Get the Latest News and Ratings for INO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/20255,010,000 shares $10.47 million +2.5%14.0%5.1 $2.09 1/15/20254,890,000 shares $9.10 million +12.7%13.7%5.3 $1.86 12/31/20244,340,000 shares $7.94 million -3.1%12.2%5.1 $1.83 12/15/20244,480,000 shares $10.39 million +18.5%12.6%6.8 $2.32 11/30/20243,780,000 shares $16.33 million +0.8%14.7%10.5 $4.32 11/15/20243,750,000 shares $15.99 million +7.1%14.5%11.2 $4.27 10/31/20243,500,000 shares $18.48 million +0.6%13.6%12 $5.28 10/15/20243,480,000 shares $19.42 million +4.2%13.5%11.5 $5.58 9/30/20243,340,000 shares $19.31 million +9.5%13.0%10.1 $5.78 9/15/20243,050,000 shares $20.77 million +1.7%11.9%8.3 $6.81 8/31/20243,000,000 shares $21.66 million +2.7%11.7%8.3 $7.22 8/15/20242,920,000 shares $22.78 million +9.0%11.3%7.9 $7.80 7/31/20242,680,000 shares $28.57 million -4.3%10.4%7.1 $10.66 7/15/20242,800,000 shares $30.97 million +37.3%10.9%7.6 $11.06 6/30/20242,040,000 shares $16.48 million +9.1%7.9%5.6 $8.08 6/15/20241,870,000 shares $17.00 million No Change7.3%5.5 $9.09 5/31/20241,870,000 shares $18.94 million -12.6%7.3%4.9 $10.13 5/15/20242,140,000 shares $27.97 million +5.4%8.3%4.9 $13.07 4/30/20242,030,000 shares $23.24 million -10.2%7.9%4.4 $11.45 4/15/20242,260,000 shares $24.84 million +7.6%8.9%4.6 $10.99 3/31/20242,100,000 shares $29.15 million +1.9%9.1%3.9 $13.88 3/15/20242,060,000 shares $22.10 million +10.8%9.0%3.9 $10.73 2/29/20241,860,000 shares $16.48 million +6.9%8.1%3.9 $8.86 2/15/20241,740,000 shares $12.95 million +21.7%7.8%4.4 $7.44 1/31/20241,430,000 shares $7.71 million -23.9%6.4%4.2 $5.39 1/15/202422,510,000 shares $207.99 million -5.8%N/A6.3 $9.24 12/31/202323,890,000 shares $12.18 million -1.6%N/A5.5 $0.51 12/15/202324,270,000 shares $9.44 million -5.7%N/A7 $0.39 11/30/202325,730,000 shares $10.14 million -0.9%N/A7.5 $0.39 11/15/202325,950,000 shares $9.87 million +4.1%N/A7.6 $0.38“All the land that you see I will give to you and your offspring forever…” (Ad)“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.Watch Jim Rickards reveal the Old Testament Wealth Code 10/31/202324,940,000 shares $9.09 million -3.0%N/A7.3 $0.36 10/15/202325,710,000 shares $13.18 million +72.6%N/A7.4 $0.51 9/30/202314,900,000 shares $5.80 million -4.7%N/A4.7 $0.39 9/15/202315,630,000 shares $6.25 million -6.4%N/A3.6 $0.40 8/31/202316,700,000 shares $7.51 million -24.3%N/A2.5 $0.45 8/15/202322,060,000 shares $9.93 million +2.2%N/A2.8 $0.45 7/31/202321,580,000 shares $11.48 million +3.2%N/A2.5 $0.53 7/15/202320,920,000 shares $10.98 million -13.2%N/A2.3 $0.53 6/30/202324,110,000 shares $10.77 million -45.0%N/A2.5 $0.45 6/15/202343,830,000 shares $22.18 million +2.5%N/A4.7 $0.51 5/31/202342,780,000 shares $25.61 million +9.0%N/A6.4 $0.60 5/15/202339,250,000 shares $30.13 million -0.7%N/A6.8 $0.77 4/30/202339,510,000 shares $30.52 million -0.4%N/A7.7 $0.77 4/15/202339,650,000 shares $33.81 million +13.9%N/A7.5 $0.85 3/31/202334,820,000 shares $28.55 million -11.9%N/A7 $0.82 3/15/202339,520,000 shares $45.45 million -1.8%N/A8.8 $1.15 2/28/202340,260,000 shares $50.73 million -0.4%N/A8.5 $1.26 2/15/202340,410,000 shares $62.64 million -7.6%N/A8.3 $1.55 1/31/202343,740,000 shares $72.61 million -2.3%N/A7.9 $1.66 1/15/202344,790,000 shares $85.10 million +0.1%N/A7.9 $1.90 12/30/202244,760,000 shares $69.83 million -0.5%N/A7.9 $1.56 12/15/202244,990,000 shares $79.18 million +4.0%N/A7.9 $1.76 11/30/202243,270,000 shares $88.27 million -6.2%N/A7.4 $2.04 11/15/202246,150,000 shares $115.38 million +5.7%N/A7.9 $2.50 10/31/202243,670,000 shares $94.33 million -4.2%N/A7.6 $2.16 10/15/202245,570,000 shares $71.09 million +1.5%N/A8.1 $1.56 9/30/202244,920,000 shares $77.49 million -1.8%N/A7.9 $1.73 9/15/202245,730,000 shares $96.03 million +0.3%N/A7.7 $2.10 8/31/202245,590,000 shares $104.40 million +1.2%N/A7.3 $2.29 8/15/202245,060,000 shares $125.72 million +3.1%N/A7 $2.79 7/31/202243,700,000 shares $86.53 million +0.5%N/A6.3 $1.98 7/15/202243,480,000 shares $85.66 million +7.7%N/A6.5 $1.97 6/30/202240,380,000 shares $69.86 million +12.5%N/A6.4 $1.73 6/15/202235,910,000 shares $54.58 million +4.4%N/A5.9 $1.52 5/31/202234,410,000 shares $64.35 million -20.6%N/A5.9 $1.87 5/15/202243,310,000 shares $86.19 million -4.1%N/A7.7 $1.99 4/30/202245,150,000 shares $123.26 million -0.5%N/A9.9 $2.73 4/15/202245,380,000 shares $145.22 million +1.7%N/A9.7 $3.20 3/31/202244,610,000 shares $160.15 million -3.5%N/A9.3 $3.59 3/15/202246,230,000 shares $145.16 million -7.1%N/A9.3 $3.14 2/28/202249,740,000 shares $161.16 million +5.8%24.1%10.7 $3.24 2/15/202247,000,000 shares $162.62 million -0.1%22.7%10 $3.46 1/31/202247,030,000 shares $194.70 million +5.1%22.7%9.9 $4.14 1/15/202244,740,000 shares $212.52 million -3.4%21.6%9.9 $4.75 12/31/202146,290,000 shares $230.99 million +5.7%22.4%10.9 $4.99 12/15/202143,790,000 shares $266.24 million -4.3%21.2%11 $6.08 11/30/202145,750,000 shares $331.23 million -0.4%22.1%12.2 $7.24 11/15/202145,930,000 shares $337.13 million -0.5%22.2%12.2 $7.34 10/29/202146,160,000 shares $329.58 million +0.4%22.3%11.2 $7.14 10/15/202146,000,000 shares $322.92 million +1.8%22.2%11.2 $7.02“All the land that you see I will give to you and your offspring forever…” (Ad)“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.Watch Jim Rickards reveal the Old Testament Wealth Code 9/30/202145,210,000 shares $323.70 million +1.7%21.9%10.4 $7.16 9/15/202144,450,000 shares $336.49 million +2.1%21.5%9.8 $7.57 8/31/202143,540,000 shares $376.19 million +2.3%21.1%9.3 $8.64 8/13/202142,570,000 shares $392.92 million -1.9%20.6%8.6 $9.23 7/30/202143,390,000 shares $364.48 million -4.6%21.2%8.3 $8.40 7/15/202145,500,000 shares $364 million +2.0%22.2%7 $8.00 6/30/202144,590,000 shares $413.35 million -4.6%21.8%5.7 $9.27 6/15/202146,740,000 shares $403.37 million -8.2%22.8%5.8 $8.63 5/28/202150,940,000 shares $384.60 million -9.1%24.9%5.9 $7.55 5/14/202156,010,000 shares $348.94 million +2.9%N/A5.7 $6.23 4/30/202154,460,000 shares $375.23 million +5.9%N/A4.8 $6.89 4/15/202151,430,000 shares $454.64 million -5.9%N/A3.3 $8.84 3/31/202154,640,000 shares $481.38 million -4.4%N/A3.9 $8.81 3/15/202157,170,000 shares $600.29 million +13.8%N/A3.8 $10.50 2/26/202150,230,000 shares $577.14 million +16.6%N/A3.2 $11.49 2/12/202143,090,000 shares $560.17 million -0.5%N/A2.8 $13.00 1/29/202143,310,000 shares $474.24 million -22.8%N/A2.8 $10.95 1/15/202156,070,000 shares $525.38 million -0.1%N/A4.7 $9.37 12/31/202056,140,000 shares $505.26 million +6.8%N/A5.5 $9.00 12/15/202052,560,000 shares $547.15 million -5.1%N/A4.6 $10.41 11/30/202055,370,000 shares $678.84 million -6.3%N/A3.4 $12.26 11/15/202059,080,000 shares $662.88 million +4.1%N/A3.7 $11.22 10/30/202056,760,000 shares $595.41 million +3.1%N/A3.5 $10.49 10/15/202055,040,000 shares $667.64 million -3.9%N/A3 $12.13 9/30/202057,250,000 shares $664.10 million +0.1%N/A2.6 $11.60 9/15/202057,220,000 shares $779.91 million +10.4%N/A1.8 $13.63 8/31/202051,820,000 shares $621.32 million +9.6%N/A1.7 $11.99 8/14/202047,280,000 shares $698.80 million +23.1%N/A1.5 $14.78 7/31/202038,400,000 shares $746.50 million +29.7%N/A1.1 $19.44 INO Short Interest - Frequently Asked Questions What is Inovio Pharmaceuticals' current short interest? Short interest is the volume of Inovio Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of June 30th, traders have sold 5,500,000 shares of INO short. 10.88% of Inovio Pharmaceuticals' shares are currently sold short. Learn More on Inovio Pharmaceuticals' current short interest. What is a good short interest ratio for Inovio Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INO shares currently have a short interest ratio of 4.0. Learn More on Inovio Pharmaceuticals's short interest ratio. What is a good short interest percentage for Inovio Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.88% of Inovio Pharmaceuticals' floating shares are currently sold short. Is Inovio Pharmaceuticals' short interest increasing or decreasing? Inovio Pharmaceuticals saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 5,500,000 shares, a decline of 14.9% from the previous total of 6,460,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Inovio Pharmaceuticals' float size? Inovio Pharmaceuticals currently has issued a total of 36,670,000 shares. Some of Inovio Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Inovio Pharmaceuticals currently has a public float of 50,560,000 shares. How does Inovio Pharmaceuticals' short interest compare to its competitors? 10.88% of Inovio Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies compare to Inovio Pharmaceuticals: Moderna, Inc. (19.15%), TriSalus Life Sciences, Inc. (3.46%), Profound Medical (2.07%), CVRx, Inc. (11.48%), KORU Medical Systems, Inc. (3.12%), Electromed, Inc. (5.79%), LENSAR, Inc. (5.02%), Pro-Dex, Inc. (10.97%), Avita Medical Inc. (22.32%), Lakeland Industries, Inc. (10.03%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Inovio Pharmaceuticals stock? Short selling INO is an investing strategy that aims to generate trading profit from Inovio Pharmaceuticals as its price is falling. INO shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Inovio Pharmaceuticals? A short squeeze for Inovio Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of INO, which in turn drives the price of the stock up even further. How often is Inovio Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INO, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies MRNA Short Interest Data TLSI Short Interest Data PROF Short Interest Data CVRX Short Interest Data KRMD Short Interest Data ELMD Short Interest Data LNSR Short Interest Data PDEX Short Interest Data RCEL Short Interest Data LAKE Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INO) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
